{
    "eid": "2-s2.0-84992694913",
    "title": "Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial",
    "cover-date": "2016-11-01",
    "subject-areas": [
        {
            "$": "Hematology",
            "@code": "2720"
        }
    ],
    "keywords": [],
    "authors": [
        "Jes\u00fas F. San-Miguel"
    ],
    "citedby-count": 121,
    "ref-count": 26,
    "ref-list": [
        "Improved survival in multiple myeloma and the impact of novel therapies",
        "Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients",
        "Clinical course of patients with relapsed multiple myeloma",
        "Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study",
        "Aggresome induction by proteasome inhibitor bortezomib and \u03b1-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells",
        "Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma",
        "Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma",
        "In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma",
        "A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma",
        "Blood",
        "Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial",
        "Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma",
        "Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment",
        "Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma",
        "Proc Am Soc Clin Oncol",
        "Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived",
        "Blood",
        "Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma",
        "Blood",
        "Clinically relevant end points and new drug approvals for myeloma",
        "Time-dependent endpoints as predictors of overall survival in multiple myeloma",
        "Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: Pharmacology and clinical outcomes",
        "Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study",
        "Efficacy and safety of once-weekly bortezomib in multiple myeloma patients",
        "Blood",
        "Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Seongnam",
            "affilname": "Gachon University",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Warsaw",
            "affilname": "Medical University of Warsaw",
            "affiliation-country": "Poland"
        },
        {
            "affiliation-city": "Alexandria",
            "affilname": "Alexandria University",
            "affiliation-country": "Egypt"
        },
        {
            "affiliation-city": "Wurzburg",
            "affilname": "Universit\u00e4tsklinikum W\u00fcrzburg",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Athens",
            "affilname": "National and Kapodistrian University of Athens",
            "affiliation-country": "Greece"
        },
        {
            "affiliation-city": "Nantes",
            "affilname": "CHU de Nantes",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Seoul",
            "affilname": "Seoul National University Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Pamplona",
            "affilname": "Cl\u00ednica Universidad de Navarra",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Boston",
            "affilname": "Dana-Farber Cancer Institute",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Rueil-Malmaison",
            "affilname": "Novartis Pharma S.A.S.",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Shanghai",
            "affilname": "Changzheng Hospital",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Ankara",
            "affilname": "Ankara \u00dcniversitesi",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Kiel",
            "affilname": "Christian-Albrechts-Universit\u00e4t zu Kiel",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Basel",
            "affilname": "Novartis International AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Vila Buarque",
            "affilname": "Irmandade da Santa Casa de Misericordia de Sao Paulo",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Atlanta",
            "affilname": "Emory University",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Novartis Pharmaceuticals Corporation"
    ]
}